New eczema pill shows promise in Mid-Stage trial
NCT ID NCT07441395
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a daily pill called soquelitinib in 200 adults with moderate to severe atopic dermatitis (eczema). Participants take either the drug or a placebo for 12 weeks, and doctors track skin improvements and side effects. The goal is to see if soquelitinib can safely reduce eczema severity better than a dummy pill.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- soquelitinib
- What this could lead to
- If it works, this could point toward a new daily pill option for people with moderate to severe eczema that is not well controlled by current treatments.
- What could go wrong
- This is an early Phase 2 trial with only 200 participants, so results may not apply to everyone. It is also compared to a placebo, so the real benefit may be small or absent, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Corvus Clinical Trials
RECRUITINGSouth San Francisco, California, 94080, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection calm severe eczema when creams fall short?
- Can a new biologic calm severe eczema?
- Can a daily probiotic soothe colicky babies and calm eczema?
- Can a new injection match an existing eczema treatment?
- Can Real-World data unlock better skin disease care?
- Can a meditation app soothe teen eczema?